Logo
x

Search

Subscribe Now

Eli lilly

Eli Lilly Reports the P-III (SUMMIT) Trial Data of Tirzepatide to Treat Heart Failure with Preserved Ejection Fraction and Obesity

Eli Lilly Reports the P-III (SUMMIT) Trial Data of Tirzepatide to Treat Heart Failure with Preserved Ejection Fraction and Obesity

  • August 2, 2024
Eli Lilly to Acquire Morphic Holdings for an Aggregate of ~$3.2B

Eli Lilly to Acquire Morphic Holdings for an Aggregate of ~$3.2B

  • July 8, 2024
Eli Lilly Reports the US FDA’s Approval of Kisunla (donanemab-azbt) to Treat Early Symptomatic Alzheimer's Disease

Eli Lilly Reports the US FDA’s Approval of Kisunla (donanemab-azbt) to Treat Early Symptomatic Alzheimer's Disease

  • July 3, 2024
Eli Lilly Reports Detailed Data from the P-III (SURMOUNT-OSA) Trial of Tirzepatide to Treat Obstructive Sleep Apnea

Eli Lilly Reports Detailed Data from the P-III (SURMOUNT-OSA) Trial of Tirzepatide to Treat Obstructive Sleep Apnea

  • June 24, 2024
Eli Lilly Reports the P-II (SYNERGY-NASH) Study Data of Tirzepatide for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Eli Lilly Reports the P-II (SYNERGY-NASH) Study Data of Tirzepatide for Treating Metabolic Dysfunction-Associated Steatohepatitis...

  • June 10, 2024
Eli Lilly Highlights the P-I/II Trial Data of Olomorasib for Treating Advanced Solid Tumors at ASCO 2024

Eli Lilly Highlights the P-I/II Trial Data of Olomorasib for Treating Advanced Solid Tumors at ASCO 2024

  • June 3, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.